Immune Checkpoint Inhibitor Combination Therapy for Renal Cell Carcinomas With Concomitant Inferior Vena Cava Thrombi.

Kazuhiko Yoshida, Keisuke Hata, Junpei Iizuka, Tsunenori Kondo, Hiroki Ishihara, Hideki Ishida, Yoji Nagashima, Kazunari Tanabe, Toshio Takagi

In vivo (Athens, Greece) 2022 Mar-Apr

filter terms:

The efficacy of immune checkpoint inhibitor (ICI) combinations in treating inferior vena cava (IVC) tumour thrombi has not yet been reported. We aimed to evaluate the clinical efficacy of ICIs for patients with renal cell carcinoma (RCC) and a concomitant IVC tumour thrombus. Three men and two women with RCC and an IVC tumour thrombus were administered ICIs in 2020-2021. Three and two patients received nivolumab plus ipilimumab and pembrolizumab plus axitinib therapy, respectively. All ICI-treated patients showed tumour shrinkage. The IVC thrombus level was downstaged in two patients. The mean reduction in maximum primary tumour diameter and IVC thrombus height was 34 and 33 mm, respectively. Presurgical ICI therapy in three patients who underwent radical nephrectomy with thrombectomy resulted in a modified surgical strategy and approach and reduced surgical risk. Thus, ICIs may treat select cases of RCC with an IVC tumour thrombus effectively. Copyright © 2022, International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.

Citation

Kazuhiko Yoshida, Keisuke Hata, Junpei Iizuka, Tsunenori Kondo, Hiroki Ishihara, Hideki Ishida, Yoji Nagashima, Kazunari Tanabe, Toshio Takagi. Immune Checkpoint Inhibitor Combination Therapy for Renal Cell Carcinomas With Concomitant Inferior Vena Cava Thrombi. In vivo (Athens, Greece). 2022 Mar-Apr;36(2):1030-1034